

Top Enrolling Physicians for July 2012

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Biggers	2	0	2	2
Dr. Braun	2	0	0	0
Dr. Carlson	7	3.6	3	6.6
Dr. Holden	1	0	1	1
Dr. Kent	1	1	0.5	1.5
Dr. Raju	1	0	1	1
Dr. Tiriveedhi	1	0	1	1
Dr. Zoghbi	1	1.5	0	1.5
TOTALS	16	6.1	8.5	14.6

To reach our NCI accrual goals we need to earn 9.2 treatment credits and 6.6 control credits each month. This month we did well with control credits earning 8.5, exceeding our target by 1.9 credits. However, we were 3.1 behind with treatment credits earning 6.1 this month.

CRO in Comparison to other CCOP's for grant year 2011 – 2012

Overall CRO earned 104% of our targeted credits while all CCOP's averaged 86% of their target credits this past grant year. Thanks to everyone for your contribution to our success as a CCOP. We do a great job! Below is a table comparing CRO's achievement over the past grant year with the other 64 CCOPs/MBCCOP's.

Treatment

Range=12% - 184%

Number of CCOPs	% of 12-month goal achieved*
9 (14%)	95 - ≥ 100%
19 (30%)	76 – 94%
*CRO 93%	
22 (34%)	51 – 75%
9 (14%)	26 – 50%
5 (8%)	≤ 10 – 25%

Cancer Control

Range=23% - 311%

Number of CCOPs	% of 12-month goal achieved*		Number of CCOPs/	% of 12-month goal achieved*
30(47%)	95 - ≥ 100%		15(23%)	95 - ≥ 100%
*CRO 127%			*CRO 104%	
9 (14%)	76 – 94%		25 (39%)	76 – 94%
11 (17%)	51 – 75%		15 (23%)	51 – 75%
12 (19%)	26 – 50%		7 (11%)	26 – 50%
2 (3%)	≤ 10 – 25%	-	2 (3%)	≤ 10 – 25%

Total Accrual Goals

Range= 19% - 152%

Financial Conflict of Interest Policy

All CRO investigators and staff should have received a letter in the mail including a copy of CRO's SOP #18 "Financial Conflict of Interest" and disclosure forms. Institutions receiving federal funding (including CRO) are required to comply with Public Health Service (PHS) regulations on Responsibility of applicants for Promoting Objectivity in Research for which PHS Funding is sought and (45 C.F.R. Part 50) and Responsible Prospective Contracts (45 C.F.R. Part 94) by August 24, 2012. ***CRO investigators and staff who have not completed the training and signed the disclosure documents will not be able to participate in CRO research after August 24th.*** If you have any questions please give us a call at 417-269-4520.

Monthly Educational Conferences dates for August

CRO's **only** educational conference will be on Monday, August 13th at 12noon this month. We will provide training on Financial Conflicts of Interest.

Cooperative Base Audits

GOG will be with CRO on Monday, August 20th for their required 3-year audit. SWOG will be with us two days later on August 22nd and 23rd.

New Studies Approved in July 2012

Opened at Cox and Mercy Springfield

CTSU CALGB 50904 A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

RTOG 1115 Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer

Opened at Cox Springfield Only

GOG-0244 The Lymphedema and Gynecologic Cancer (LEG) Study; Incidence, Risk Factors, and Impact in Newly Diagnosed Patients

Studies Permanently Closed to Enrollment at Cox & Mercy in July 2012)

CTSU ACOSOG A1071 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis

CTSU NCCTG N0733

Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 In Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane